MINI-FOCUS: CELL-BASED THERAPY
Controlled Delivery of Basic Fibroblast Growth Factor Promotes Human Cardiosphere-Derived Cell Engraftment to Enhance Cardiac Repair for Chronic Myocardial Infarction
Naofumi Takehara, MD, PhD*,
Yoshiaki Tsutsumi, MD, PhD||,
Kento Tateishi, MD, PhD*,||,
Takehiro Ogata, MD, PhD*,
Hideo Tanaka, MD, PhD¶,
Tomomi Ueyama, MD, PhD*,
Tomosaburo Takahashi, MD, PhD*,||,
Tetsuro Takamatsu, MD, PhD¶,
Masanori Fukushima, MD, PhD ,
Masashi Komeda, MD, PhD ,
Masaaki Yamagishi, MD, PhD#,
Hitoshi Yaku, MD, PhD#,
Yasuhiko Tabata, PhD, DMedSci, Dpharm ,
Hiroaki Matsubara, MD, PhD*,||,* and
Hidemasa Oh, MD, PhD*,*
* Department of Experimental Therapeutics, Translational Research Center, Kyoto University, Kyoto, Japan
Division of Clinical Trial Design and Management, Translational Research Center, Kyoto University, Kyoto, Japan
Department of Biomaterials, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
Department of Cardiovascular Surgery, Toyohashi Heart Center, Toyohashi, Japan
|| Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
¶ Department of Pathology and Cell Regulation, Kyoto Prefectural University of Medicine, Kyoto, Japan
# Department of Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
Manuscript received March 7, 2008;
revised manuscript received June 4, 2008,
accepted June 10, 2008.
* Reprint requests and correspondence: Dr. Hidemasa Oh or Dr. Hiroaki Matsubara, Department of Experimental Therapeutics, Translational Research Center, Kyoto University Hospital, Kyoto 606-8507, Japan (Email: matsubah{at}koto.kpu-m.ac.jp).
Objectives: This study was designed to determine whether controlled release of basic fibroblast growth factor (bFGF) might improve human cardiosphere-derived cell (hCDC) therapy in a pig model of chronic myocardial infarction.
Background: Current cell therapies for cardiac repair are limited by loss of the transplanted cells and poor differentiation.
Methods: We conducted 2 randomized, placebo-controlled studies in immunosuppressed pigs with anterior myocardial infarctions. Four weeks after coronary reperfusion, 14 pigs were randomly assigned to receive an intramyocardial injection of placebo medium with or without bFGF-incorporating hydrogel implantation. As a second study, 26 pigs were randomized to receive controlled release of bFGF combined with or without hCDCs or bone marrow–derived mesenchymal stem cell transplantation 4 weeks after reperfusion.
Results: Controlled release of bFGF in ischemic myocardium significantly augmented the formation of microvascular networks to enhance myocardial perfusion and contractile function. When combined with cell transplantation, the additive effects of bFGF were confined to hCDC-injected animals, but were not observed in animals receiving human bone marrow–derived mesenchymal stem cell transplantation. This was shown by increased donor-cell engraftment and enhanced cardiomyocyte differentiation in the transplanted hearts, resulting in synergistically improved ventricular function and regional wall motion and reduced infarct size.
Conclusions: Controlled delivery of bFGF modulates the post-ischemic microenvironment to enhance hCDC engraftment and differentiation. This novel strategy demonstrates significant functional improvements after myocardial infarction and may potentially represent a therapeutic approach to be studied in a clinical trial in human heart failure.
Key Words: cell therapy • bFGF • gelatin hydrogel • heart failure • myocardial infarction
|
Abbreviations and Acronyms
| | bFGF = basic fibroblast growth factor | | DMEM = Dulbecco's Modified Eagle Medium | | FISH = fluorescent in situ hybridization | | hBMC = human bone marrow–derived mesenchymal stem cell | | hCDC = human cardiosphere-derived cell | | LV = left ventricle/ventricular | | LVEF = left ventricular ejection fraction | | MRI = magnetic resonance imaging | | SPIO = superparamagnetic iron oxide | | SRS = systolic radial strain |
|
Related Articles
-
Better Regenerative Output After Cellular Input: Healing Hearts by Combining Basic Fibroblast Factor and Cell-Based Therapy
- Stefanie Dimmeler and Marc Tjwa
J. Am. Coll. Cardiol. 2008 52: 1866-1868.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A40.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
K. Malliaras, T.-S. Li, D. Luthringer, J. Terrovitis, K. Cheng, T. Chakravarty, G. Galang, Y. Zhang, F. Schoenhoff, J. Van Eyk, et al.
Safety and Efficacy of Allogeneic Cell Therapy in Infarcted Rats Transplanted With Mismatched Cardiosphere-Derived Cells
Circulation,
January 3, 2012;
125(1):
100 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zisa, A. Shabbir, M. Mastri, T. Taylor, I. Aleksic, M. McDaniel, G. Suzuki, and T. Lee
Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair
Am J Physiol Heart Circ Physiol,
December 1, 2011;
301(6):
H2422 - H2432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Takehara and H. Matsubara
Cardiac regeneration therapy: connections to cardiac physiology
Am J Physiol Heart Circ Physiol,
December 1, 2011;
301(6):
H2169 - H2180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. White, R. R. Smith, S. Matsushita, T. Chakravarty, L. S. C. Czer, K. Burton, E. R. Schwarz, D. R. Davis, Q. Wang, N. L. Reinsmoen, et al.
Intrinsic cardiac origin of human cardiosphere-derived cells
Eur. Heart J.,
June 9, 2011;
(2011)
ehr172v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Malliaras and E. Marban
Cardiac cell therapy: where we've been, where we are, and where we should be headed
Br. Med. Bull.,
June 1, 2011;
98(1):
161 - 185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Chimenti, R. R. Smith, T.-S. Li, G. Gerstenblith, E. Messina, A. Giacomello, and E. Marban
Relative Roles of Direct Regeneration Versus Paracrine Effects of Human Cardiosphere-Derived Cells Transplanted Into Infarcted Mice
Circ. Res.,
March 19, 2010;
106(5):
971 - 980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Chavakis, M. Koyanagi, and S. Dimmeler
Enhancing the Outcome of Cell Therapy for Cardiac Repair: Progress From Bench to Bedside and Back
Circulation,
January 19, 2010;
121(2):
325 - 335.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kakkar and R. T. Lee
Intramyocardial Fibroblast Myocyte Communication
Circ. Res.,
January 8, 2010;
106(1):
47 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. V. Johnston, T. Sasano, K. Mills, R. Evers, S.-T. Lee, R. R. Smith, A. C. Lardo, S. Lai, C. Steenbergen, G. Gerstenblith, et al.
Engraftment, Differentiation, and Functional Benefits of Autologous Cardiosphere-Derived Cells in Porcine Ischemic Cardiomyopathy
Circulation,
September 22, 2009;
120(12):
1075 - 1083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Boudoulas and A. K. Hatzopoulos
Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease
Dis. Model. Mech.,
July 1, 2009;
2(7-8):
344 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Forrester, R. R. Makkar, and E. Marban
Long-Term Outcome of Stem Cell Therapy for Acute Myocardial Infarction: Right Results, Wrong Reasons
J. Am. Coll. Cardiol.,
June 16, 2009;
53(24):
2270 - 2272.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tabata
Biomaterial technology for tissue engineering applications
J R Soc Interface,
June 6, 2009;
6(Suppl_3):
S311 - S324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dimmeler and M. Tjwa
Better Regenerative Output After Cellular Input: Healing Hearts by Combining Basic Fibroblast Factor and Cell-Based Therapy
J. Am. Coll. Cardiol.,
December 2, 2008;
52(23):
1866 - 1868.
[Full Text]
[PDF]
|
|
|
|
